Oslo, Norway, 25 August 2025 – AdjuTec Pharma AS, a privately held company developing antibiotic resistance breakers, today announces that it has signed a consortium agreement after a positive feedback from the Eurostars evaluators.
AdjuTec Pharma applied for Eurostars funding on behalf of a consortium of four SME partners. The program will investigate new antibiotics for the treatment of patients with severe lung infections caused by multidrug-resistant bacteria. Program activities include microbiology, toxicology, drug formulation and clinical testing in healthy volunteers. The consortium is headed by AdjuTec Pharma who will perform in vitro microbiology screening and toxicology testing. Our partners are:
The consortium will investigate the most efficient drug combination of selected multidrug resistant bacterial strains and secure adequate drug dosing to the lungs. The Eurostars project will run for three years and starts end 2025.
Lung infections are caused by different bacteria increasingly resistant to modern antibiotics. In this program, AdjuTec Pharma’s novel resistance breaker APC148 that recently completed a phase 1 safety study, will be tested in combination with different antibiotics. The company’s lead product APC301 has shown excellent in vitro and in vivo efficacy towards several multidrug resistant bacteria and showed most recently superiority to all competitor products in a global collection of 176 pathogens (Enterobacterales). The Eurostars program includes preclinical and clinical activities targeting major pathogens causing severe hospital lung infections. The project is anticipated to expand AdjuTec Pharma´s value proposition.
AdjuTec Pharma applied for Eurostars funding on behalf of a consortium of four SME partners. The program will investigate new antibiotics for the treatment of patients with severe lung infections caused by multidrug-resistant bacteria. Program activities include microbiology, toxicology, drug formulation and clinical testing in healthy volunteers. The consortium is headed by AdjuTec Pharma who will perform in vitro microbiology screening and toxicology testing. Our partners are:
- Vivexia (France), a leading laboratory who will perform in vivo microbiology testing
- PureIMS (The Netherlands), based on its proprietary inhaler, will develop and investigate inhalation characteristics of the formulation
- CTC (Sweden), a clinical CRO who will test lung availability of test compounds in healthy volunteers
The consortium will investigate the most efficient drug combination of selected multidrug resistant bacterial strains and secure adequate drug dosing to the lungs. The Eurostars project will run for three years and starts end 2025.
Lung infections are caused by different bacteria increasingly resistant to modern antibiotics. In this program, AdjuTec Pharma’s novel resistance breaker APC148 that recently completed a phase 1 safety study, will be tested in combination with different antibiotics. The company’s lead product APC301 has shown excellent in vitro and in vivo efficacy towards several multidrug resistant bacteria and showed most recently superiority to all competitor products in a global collection of 176 pathogens (Enterobacterales). The Eurostars program includes preclinical and clinical activities targeting major pathogens causing severe hospital lung infections. The project is anticipated to expand AdjuTec Pharma´s value proposition.
AdjuTec Pharma AS, COO and project coordinator, Bjørn Klem comments:
“The signing of the Eurostars consortium agreement is exciting news for AdjuTec Pharma as it will expand our technology into a new patient population with severe lung infection. Together with our partners we will investigate new drug combinations and formulations to broaden the commercial potential of partner technologies and competences.”
About antimicrobial resistance (AMR) – https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
About AdjuTec Pharma AS
AdjuTec Pharma is a company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The company´s technology offers a unique mechanism of action that inactivates bacterial defence enzymes and restores bacterial sensitivity to antibiotics. The company’s lead product is APC148, a selective zinc chelator targeting bacterial metallo-b-lactamase (MBL) enzymes. The technology was invented by Professor Emeritus Pål Rongved and his group at the Department of Pharmacy, University of Oslo. The company is located at Rebel, St Olavs Plass 5 - downtown Oslo.
For more information, please visit www.adjutecpharma.com
Please contact: info@adjutecpharma.com
Follow us on LinkedIn
Acknowledgments
We would like to express our gratitude to Neon Innovation for their invaluable support in the preparation and submission of another successful grant application as well as our partners, the Research Council of Norway, Vinnova (Sweden), RVO (The Netherlands), BPI (France) and the Eurostars program for funding this project.